- Home
- IMMX vs VATE Comparison
IMMX vs VATE Comparison
Compare IMMX & VATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMX
- VATE
- Stock Information
- Founded
- IMMX 2014
- VATE 1994
- Country
- IMMX United States
- VATE United States
- Employees
- IMMX N/A
- VATE N/A
- Industry
- IMMX Medicinal Chemicals and Botanical Products
- VATE Metal Fabrications
- Sector
- IMMX Health Care
- VATE Industrials
- Exchange
- IMMX Nasdaq
- VATE Nasdaq
- Market Cap
- IMMX 61.1M
- VATE 82.6M
- IPO Year
- IMMX 2021
- VATE 1996
- Fundamental
- Price
- IMMX $2.17
- VATE $5.28
- Analyst Decision
- IMMX Strong Buy
- VATE
- Analyst Count
- IMMX 1
- VATE 0
- Target Price
- IMMX $7.00
- VATE N/A
- AVG Volume (30 Days)
- IMMX 269.5K
- VATE 48.4K
- Earning Date
- IMMX 11-12-2024
- VATE 11-06-2024
- Dividend Yield
- IMMX N/A
- VATE N/A
- EPS Growth
- IMMX N/A
- VATE N/A
- EPS
- IMMX N/A
- VATE N/A
- Revenue
- IMMX N/A
- VATE $1,231,500,000.00
- Revenue This Year
- IMMX N/A
- VATE N/A
- Revenue Next Year
- IMMX $200.00
- VATE N/A
- P/E Ratio
- IMMX N/A
- VATE N/A
- Revenue Growth
- IMMX N/A
- VATE N/A
- 52 Week Low
- IMMX $1.26
- VATE $3.25
- 52 Week High
- IMMX $7.50
- VATE $13.00
- Technical
- Relative Strength Index (RSI)
- IMMX 53.37
- VATE 46.38
- Support Level
- IMMX $1.88
- VATE $5.09
- Resistance Level
- IMMX $2.44
- VATE $6.48
- Average True Range (ATR)
- IMMX 0.32
- VATE 0.47
- MACD
- IMMX -0.02
- VATE -0.12
- Stochastic Oscillator
- IMMX 34.94
- VATE 13.48
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
About VATE INNOVATE Corp.
Innovate Corp is a diversified holding company that has a portfolio of subsidiaries in a variety of operating segments which are; The infrastructure segment is comprised of DBM Global Inc, a fully integrated industrial construction, structural steel, and facility maintenance provider that provides fabrication and erection of structural steel and heavy steel plate services, The Life Sciences segment is comprised of Pansend Life Sciences which seeks to develop products to treat early osteoarthritis of the knee and aesthetic and medical technologies for the skin, and Spectrum segment is comprised of HC2 Broadcasting Holdings Inc which operates over-the-air broadcasting stations across the United States.